Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma

Cancer Gene Therapy volume 29, pages 1819–1826 (2022)Cite this article

Subjects

Abstract

Uveal melanoma (UM) is a rare, genetically bland ocular malignancy with excellent local treatment options, but no disease-specific therapies are approved for use in the metastatic setting by the Food and Drug Administration. Metastatic UM (mUM) confers a prognosis of ~15 months. Unlike cutaneous melanoma, UM is poorly responsive to checkpoint inhibitors and cytotoxic chemotherapy highlighting the importance of clarifying vulnerable disease-specific mechanisms, such as cell cycle or metabolic pathways necessary for tumor growth and survival. The elucidation of signaling pathways downstream of the frequently mutated GNA GTPase such as PKC/MAPK/ERK/MEK, PI3K/AKT, and YAP-Hippo have offered potential targets. Potentially druggable epigenetic targets due to BAP1-mutated UM have also been identified, including proteins involved with histone deacetylation and DNA splicing. This review describes the preclinical rationale for the development of targeted therapies and current strategies currently being studied in clinical trials or will be in the near future.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The Gα signaling pathway in uveal melanoma.
Fig. 2: Targetable epigenetic drivers of uveal melanoma.

Similar content being viewed by others

References

  1. Rantala ES, Hernberg M, Kivelä TT. Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis. Melanoma Res. 2019;29:561–8.

    Article  Google Scholar 

  2. Khoja L, Atenafu EG, Suciu S, Leyvraz S, Sato T, Marshall E, et al. Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study. Ann Oncol. 2019;30:1370–80.

    Article  CAS  Google Scholar 

  3. Nathan P, Hassel JC, Rutkowski P, Baurain J-F, Butler MO, Schlaak M, et al. Overall survival benefit with tebentafusp in metastatic uveal melanoma. N. Engl J Med. 2021;385:1196–206.

    Article  CAS  Google Scholar 

  4. Decatur CL, Ong E, Garg N, Anbunathan H, Bowcock AM, Field MG, et al. Driver mutations in uveal melanoma: associations with gene expression profile and patient outcomes. JAMA Ophthalmol. 2016;134:728–33.

    Article  Google Scholar 

  5. Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, et al. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun. 2018;9:116.

    Article  Google Scholar 

  6. Smit KN, Jager MJ, de Klein A, Kiliҫ E. Uveal melanoma: towards a molecular understanding. Prog Retinal Eye Res. 2020;75:100800.

    Article  Google Scholar 

  7. Ceraudo E, Horioka M, Mattheisen JM, Hitchman TD, Moore AR, Kazmi MA, et al. Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. Journal of Biological Chemistry. 2021;296:100163.

    Article  CAS  Google Scholar 

  8. Gusach A, Luginina A, Marin E, Brouillette RL, Besserer-Offroy É, Longpré JM, et al. Structural basis of ligand selectivity and disease mutations in cysteinyl leukotriene receptors. Nat Commun. 2019;10:5573.

    Article  CAS  Google Scholar 

  9. Singh RK, Gupta S, Dastidar S, Ray A. Cysteinyl leukotrienes and their receptors: molecular and functional characteristics. Pharmacology. 2010;85:336–49.

    Article  CAS  Google Scholar 

  10. Nell RJ, Menger NV, Versluis M, Luyten GPM, Verdijk RM, Madigan MC, et al. Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma. BMC Cancer. 2021;21:164.

    Article  CAS  Google Scholar 

  11. Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, et al. Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer cell. 2017;32:204–20. e15

    Article  CAS  Google Scholar 

  12. Urtatiz O, Van Raamsdonk CD. Gnaq and Gna11 in the endothelin signaling pathway and melanoma. Front Genet. 2016;7:59

    Article  Google Scholar 

  13. Yang J, Manson DK, Marr BP, Carvajal RD. Treatment of uveal melanoma: where are we now? Therapeutic Adv Med Oncol. 2018;10:1758834018757175.

    Google Scholar 

  14. Vivet-Noguer R, Tarin M, Roman-Roman S, Alsafadi S. Emerging therapeutic opportunities based on current knowledge of uveal melanoma biology. Cancers 2019;11:1019.

    Article  CAS  Google Scholar 

  15. Ambrosini G, Pratilas CA, Qin L-X, Tadi M, Surriga O, Carvajal RD, et al. Identification of unique MEK-dependent genes in GNAQ mutant uveal melanoma involved in cell growth, tumor cell invasion, and MEK resistance. Clin Cancer Res. 2012;18:3552–61.

    Article  CAS  Google Scholar 

  16. Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol. 2017;35:40–7.

    Article  CAS  Google Scholar 

  17. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000;275:38953–6.

    Article  CAS  Google Scholar 

  18. Fernández ML, DiMattia GE, Dawson A, Bamford S, Anderson S, Hennessy BT, et al. Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines. Am J Cancer Res. 2016;6:2235–51.

    Google Scholar 

  19. Shoushtari AN, Kudchadkar RR, Panageas K, Murthy RK, Jung M, Shah R, et al. A randomized phase 2 study of trametinib with or without GSK2141795 in patients with advanced uveal melanoma. J Clin Oncol. 2016;34:9511. 15_suppl

    Article  Google Scholar 

  20. Paraiso K, Fedorenko I, Cantini L, Munko A, Hall M, Sondak V, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer. 2010;102:1724–30.

    Article  CAS  Google Scholar 

  21. Ahronian LG, Sennott EM, Van Allen EM, Wagle N, Kwak EL, Faris JE, et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 2015;5:358–67.

    Article  CAS  Google Scholar 

  22. Musi E, Ambrosini G, Munck J, Schwartz GK. Abstract 5784: a novel ERK inhibitor in the treatment of uveal melanoma. Cancer Res. 2018;78:5784.

    Article  Google Scholar 

  23. Sullivan RJ, Infante JR, Janku F, Wong DJL, Sosman JA, Keedy V, et al. First-in-class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study. Cancer Discov. 2018;8:184–95.

    Article  CAS  Google Scholar 

  24. Buchbinder EI, Cohen JV, Haq R, Hodi FS, Lawrence DP, Giobbie-Hurder A, et al. A phase II study of ERK inhibition by ulixertinib (BVD-523) in metastatic uveal melanoma. J Clin Oncol. 2020;38:10036.

    Article  Google Scholar 

  25. Falkenburger BH, Jensen JB, Dickson EJ, Suh BC, Hille B. Phosphoinositides: lipid regulators of membrane proteins. J Physiol. 2010;588:3179–85.

    Article  CAS  Google Scholar 

  26. Wu X, Li J, Zhu M, Fletcher JA, Hodi FS. Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-κB pathways. Mol Cancer Ther. 2012;11:1905–14.

    Article  CAS  Google Scholar 

  27. Koivunen J, Aaltonen V, Peltonen J. Protein kinase C (PKC) family in cancer progression. Cancer Lett. 2006;235:1–10.

    Article  CAS  Google Scholar 

  28. Martiny-Baron G, Fabbro D. Classical PKC isoforms in cancer. Pharm Res. 2007;55:477–86.

    Article  CAS  Google Scholar 

  29. Naor Z, Benard O, Seger R. Activation of MAPK cascades by G-protein-coupled receptors: the case of gonadotropin-releasing hormone receptor. Trends Endocrinol Metab. 2000;11:91–9.

    Article  CAS  Google Scholar 

  30. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS. The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS ONE. 2012;7:e29622.

    Article  CAS  Google Scholar 

  31. Piperno-Neumann S, Larkin J, Carvajal RD, Luke JJ, Schwartz GK, Hodi FS, et al. Genomic profiling of metastatic uveal melanoma and clinical results of a phase I study of the protein kinase C inhibitor AEB071. Mol Cancer Ther. 2020;19:1031.

    Article  CAS  Google Scholar 

  32. Kapiteijn E, Carlino M, Boni V, Loirat D, Speetjens F, Park J, et al. Abstract CT068: a phase I trial of LXS196, a novel PKC inhibitor for metastatic uveal melanoma. Cancer Res. 2019;79:CT068–CT.

    Article  Google Scholar 

  33. Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C, et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene. 2014;33:4724–34.

    Article  CAS  Google Scholar 

  34. Jafarnejad M, Sové RJ, Danilova L, Mirando AC, Zhang Y, Yarchoan M, et al. Mechanistically detailed systems biology modeling of the HGF/Met pathway in hepatocellular carcinoma. npj Syst Biol Appl. 2019;5:29.

    Article  Google Scholar 

  35. Demkova L, Kucerova L. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma. Mol Cancer. 2018;17:26.

    Article  Google Scholar 

  36. Wagle M-C, Ravindran N, Pankajakshan D, Lackner M, Mounir Z. Abstract 1343: preclinical evaluation of a PKC and MET inhibitor combination in metastatic uveal melanoma. Cancer Res. 2021;81:1343.

    Article  Google Scholar 

  37. Sabbah M, Najem A, Krayem M, Awada A, Journe F, Ghanem GE. RTK inhibitors in melanoma: from bench to bedside. Cancers. 2021;13:1685.

    Article  Google Scholar 

  38. Musi E, Ambrosini G, de Stanchina E, Schwartz GK. The phosphoinositide 3-kinase α selective inhibitor BYL719 enhances the effect of the protein kinase C inhibitor AEB071 in GNAQ/GNA11-mutant uveal melanoma cells. Mol Cancer Ther. 2014;13:1044–53.

    Article  CAS  Google Scholar 

  39. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18:4345–55.

    Article  CAS  Google Scholar 

  40. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4:505–18.

    Article  CAS  Google Scholar 

  41. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43:1–8.

    Google Scholar 

  42. Mattei J, Ballhausen A, Bassett R, Shephard M, Chattopadhyay C, Hudgens C, et al. A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. Melanoma Res. 2020;30:574–9.

    Article  CAS  Google Scholar 

  43. Shoushtari AN, Ong LT, Schoder H, Singh-Kandah S, Abbate KT, Postow MA, et al. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma. Melanoma Res. 2016;26:272–7.

    Article  CAS  Google Scholar 

  44. Jiang X, Zhou J, Yuen NK, Corless CL, Heinrich MC, Fletcher JA, et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin Cancer Res. 2008;14:7726–32.

    Article  CAS  Google Scholar 

  45. Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM, et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer. 2005;92:2032–8.

    Article  CAS  Google Scholar 

  46. Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G, et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012;18:4345–55.

    Article  CAS  Google Scholar 

  47. Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak AR, et al. A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest N. Drugs. 2016;34:740–9.

    Article  CAS  Google Scholar 

  48. Boopathy GTK, Hong W. Role of hippo pathway-YAP/TAZ signaling in angiogenesis. Front Cell Dev Biol. 2019;7:49

    Article  Google Scholar 

  49. Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, et al. Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell. 2014;25:822–30.

    Article  CAS  Google Scholar 

  50. Brouwer NJ, Konstantinou EK, Gragoudas ES, Marinkovic M, Luyten GPM, Kim IK, et al. Targeting the YAP/TAZ pathway in uveal and conjunctival melanoma with verteporfin. Invest. Ophthalmol Vis Sci. 2021;62:3.

    Article  CAS  Google Scholar 

  51. Arnold JJ, Blinder KJ, Bressler NM, Bressler SB, Burdan A, Haynes L, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no. 3. Am J Ophthalmol. 2004;137:683–96.

    Article  Google Scholar 

  52. Feng X, Arang N, Rigiracciolo DC, Lee JS, Yeerna H, Wang Z, et al. A platform of synthetic lethal gene interaction networks reveals that the GNAQ uveal melanoma oncogene controls the Hippo pathway through FAK. Cancer cell. 2019;35:457–72.

    Article  CAS  Google Scholar 

  53. Dawson JC, Serrels A, Stupack DG, Schlaepfer DD, Frame MC. Targeting FAK in anticancer combination therapies. Nat Rev Cancer. 2021;21:313–24.

    Article  CAS  Google Scholar 

  54. Martin M, Maßhöfer L, Temming P, Rahmann S, Metz C, Bornfeld N, et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet. 2013;45:933–6.

    Article  CAS  Google Scholar 

  55. Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet. 2013;45:133–5.

    Article  CAS  Google Scholar 

  56. Yavuzyigitoglu S, Koopmans AE, Verdijk RM, Vaarwater J, Eussen B, van Bodegom A, et al. Uveal melanomas with SF3B1 mutations: a distinct subclass associated with late-onset metastases. Ophthalmology. 2016;123:1118–28.

    Article  Google Scholar 

  57. Szalai E, Jiang Y, van Poppelen NM, Jager MJ, de Klein A, Kilic E, et al. Association of uveal melanoma metastatic rate with stochastic mutation rate and type of mutation. JAMA Ophthalmol. 2018;136:1115–20.

    Article  Google Scholar 

  58. Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, et al. The genetic evolution of metastatic uveal melanoma. Nat Genet. 2019;51:1123–30.

    Article  CAS  Google Scholar 

  59. Chokhachi Baradaran P, Kozovska Z, Furdova A, Smolkova B. Targeting epigenetic modifications in uveal melanoma. Int J Mol Sci. 2020;21:5314.

    Article  Google Scholar 

  60. Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18:408–16.

    Article  CAS  Google Scholar 

  61. Kuznetsoff JN, Owens DA, Lopez A, Rodriguez DA, Chee NT, Kurtenbach S, et al. Dual screen for efficacy and toxicity identifies HDAC inhibitor with distinctive activity spectrum for BAP1-mutant uveal melanoma. Mol Cancer Res. 2021;19:215–22.

    Article  CAS  Google Scholar 

  62. Schoumacher M, Le Corre S, Houy A, Mulugeta E, Stern M-H, Roman-Roman S, et al. Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status. Nat Med. 2016;22:577–8.

    Article  CAS  Google Scholar 

  63. Gozani O, Potashkin J, Reed R. A potential role for U2AF-SAP 155 interactions in recruiting U2 snRNP to the branch site. Mol Cell Biol. 1998;18:4752–60.

    Article  CAS  Google Scholar 

  64. Zhang J, Ali AM, Lieu YK, Liu Z, Gao J, Rabadan R, et al. Disease-causing mutations in SF3B1 alter splicing by disrupting interaction with SUGP1. Mol Cell. 2019;76:82–95.

    Article  CAS  Google Scholar 

  65. Alsafadi S, Houy A, Battistella A, Popova T, Wassef M, Henry E, et al. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage. Nat Commun. 2016;7:10615.

    Article  CAS  Google Scholar 

  66. Darman RB, Seiler M, Agrawal AA, Lim KH, Peng S, Aird D, et al. Cancer-associated SF3B1 hotspot mutations induce cryptic 3’ splice site selection through use of a different branch point. Cell Rep. 2015;13:1033–45.

    Article  CAS  Google Scholar 

  67. Bigot J, Lalanne AI, Lucibello F, Gueguen P, Houy A, Dayot S, et al. Splicing patterns in SF3B1-mutated uveal melanoma generate shared immunogenic tumor-specific neoepitopes. Cancer Discov. 2021;11:1938–51.

    Article  CAS  Google Scholar 

  68. Fong JY, Pignata L, Goy PA, Kawabata KC, Lee SC, Koh CM, et al. Therapeutic targeting of RNA splicing catalysis through inhibition of protein arginine methylation. Cancer Cell. 2019;36:194–209.

    Article  CAS  Google Scholar 

  69. Bhagwat N, Zhang Y, Lin H, Wang M, Rominger D, Emm T, et al. Abstract 2915: Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models. Cancer Res. 2020;80:2915.

    Article  Google Scholar 

  70. Fu L-l, Tian M, Li X, Li J-j, Huang J, Ouyang L, et al. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget. 2015;6:5501.

    Article  Google Scholar 

  71. Segura MF, Fontanals-Cirera B, Gaziel-Sovran A, Guijarro MV, Hanniford D, Zhang G, et al. BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. Cancer Res. 2013;73:6264–76.

    Article  CAS  Google Scholar 

  72. Chua V, Orloff M, Teh JL, Sugase T, Liao C, Purwin TJ, et al. Stromal fibroblast growth factor 2 reduces the efficacy of bromodomain inhibitors in uveal melanoma. EMBO Mol Med. 2019;11:e9081.

    Article  Google Scholar 

  73. Chi TH, Wan M, Lee PP, Akashi K, Metzger D, Chambon P, et al. Sequential roles of Brg, the ATPase subunit of BAF chromatin remodeling complexes, in thymocyte development. Immunity. 2003;19:169–82.

    Article  CAS  Google Scholar 

  74. Ho L, Crabtree GR. Chromatin remodelling during development. Nature. 2010;463:474–84.

    Article  CAS  Google Scholar 

  75. Wang W, Xue Y, Zhou S, Kuo A, Cairns BR, Crabtree GR. Diversity and specialization of mammalian SWI/SNF complexes. Genes Dev. 1996;10:2117–30.

    Article  CAS  Google Scholar 

  76. Rago F, Elliott G, Li A, Sprouffske K, Kerr G, Desplat A, et al. The discovery of SWI/SNF chromatin remodeling activity as a novel and targetable dependency in uveal melanoma. Mol Cancer Ther. 2020;19:2186–95.

    Article  CAS  Google Scholar 

  77. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature. 2009;457:599–602.

    Article  Google Scholar 

  78. Onken MD, Makepeace CM, Kaltenbronn KM, Choi J, Hernandez-Aya L, Weilbaecher KN, et al. Targeting primary and metastatic uveal melanoma with a G protein inhibitor. J Biol Chem. 2021;296:100403.

    Article  CAS  Google Scholar 

  79. Lapadula D, Farias E, Randolph CE, Purwin TJ, McGrath D, Charpentier TH, et al. Effects of oncogenic Gαq and Gα11 inhibition by FR900359 in uveal melanoma. Mol Cancer Res. 2019;17:963–73.

    Article  CAS  Google Scholar 

  80. Schrage R, Schmitz A-L, Gaffal E, Annala S, Kehraus S, Wenzel D, et al. The experimental power of FR900359 to study Gq-regulated biological processes. Nat Commun. 2015;6:10156.

    Article  CAS  Google Scholar 

  81. Pelster MS, Gruschkus SK, Bassett R, Gombos DS, Shephard M, Posada L, et al. Nivolumab and ipilimumab in metastatic uveal melanoma: results from a single-arm phase II study. J Clin Oncol. 2021;39:599–607.

    Article  CAS  Google Scholar 

  82. Piulats JM, Espinosa E, Merino LDLC, Varela M, Carrión LA, Martín-Algarra S, et al. Nivolumab plus ipilimumab for treatment-naïve metastatic uveal melanoma: an open-label, multicenter, phase II trial by the Spanish multidisciplinary melanoma group (GEM-1402). J Clin Oncol. 2021;39:586–98.

    Article  CAS  Google Scholar 

  83. Shoushtari AN, Collins L, Espinosa E, Sethi H, Stanhope S, Abdullah S, et al. 1757O early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients. Ann Oncol. 2021;32:S1210.

    Article  Google Scholar 

  84. Park JJ, Diefenbach RJ, Byrne N, Long GV, Scolyer RA, Gray ES, et al. Circulating tumor DNA reflects uveal melanoma responses to protein kinase C inhibition. Cancers. 2021;13:1740.

    Article  CAS  Google Scholar 

  85. Croce M, Ferrini S, Pfeffer U, Gangemi R. Targeted therapy of uveal melanoma: recent failures and new perspectives. Cancers. 2019;11:846.

    Article  CAS  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Alexander Z. Wei, Ashray B. Maniar.

Authors and Affiliations

  1. Columbia University Irving Medical Center, New York, New York, USA

    Alexander Z. Wei, Ashray B. Maniar & Richard D. Carvajal

Authors
  1. Alexander Z. Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ashray B. Maniar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard D. Carvajal
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AZW and ABM were responsible for designing the review, writing the report, screening potentially eligible studies, extracting and analysing data, interpreting results, updating reference lists, and creating tables. RDC was responsible for designing the review, writing the report, screening potentially eligible studies, extracting and analysing data, interpreting results, creating tables, and providing feedback on the report.

Corresponding author

Correspondence to Richard D. Carvajal.

Ethics declarations

Competing interests

RDC serves as a consultant and/or advisory board member for AstraZeneca, Aura Biosciences, Iconic Therapeutics, Janssen, Merck, Novartis, Rgenix, and Thomson Reuter. The remaining authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wei, A.Z., Maniar, A.B. & Carvajal, R.D. New targeted and epigenetic therapeutic strategies for the treatment of uveal melanoma. Cancer Gene Ther 29, 1819–1826 (2022). https://doi.org/10.1038/s41417-022-00443-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41417-022-00443-8

This article is cited by

Search

Advanced search

Quick links